Selective Genetics Inc. is looking past the common applications of gene therapy in heritable diseases and cancer, which are mainly systemic in nature, and is developing gene therapies for site-specific disorders and injuries such as dermal ulcers and peripheral nerve injuries.

Formed through the 1998 merger of Matrigen Inc. and Prizm Pharmaceuticals Inc., Selective Genetics incorporates Matrigen's Gene Activated Matrix (GAM) technology and Prizm's Directin fibroblast growth factor (FGF) gene targeting technology. Because the company believes that "there is no one approach to delivering genes, Selective Genetics looks to match strengths of vectors with clinical indications," said CEO Robert Abbott.